[go: up one dir, main page]

AU3142593A - Immunoassay using synthetic htlv-11 peptides - Google Patents

Immunoassay using synthetic htlv-11 peptides

Info

Publication number
AU3142593A
AU3142593A AU31425/93A AU3142593A AU3142593A AU 3142593 A AU3142593 A AU 3142593A AU 31425/93 A AU31425/93 A AU 31425/93A AU 3142593 A AU3142593 A AU 3142593A AU 3142593 A AU3142593 A AU 3142593A
Authority
AU
Australia
Prior art keywords
htlv
solid phase
sequence
peptide
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU31425/93A
Other versions
AU660752B2 (en
Inventor
Nrapendra Nath
Dinesh O. Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dade International Inc
Original Assignee
Baxter Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Diagnostics Inc filed Critical Baxter Diagnostics Inc
Publication of AU3142593A publication Critical patent/AU3142593A/en
Assigned to DADE INTERNATIONAL INC. reassignment DADE INTERNATIONAL INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: BAXTER DIAGNOSTICS INC.
Application granted granted Critical
Publication of AU660752B2 publication Critical patent/AU660752B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)

Description

it
JHMUJiOASSAY USING SYNTHETIC HTLV-II PEPTIDES
BACKGROUND OF THE INVENTION
1. FIELD OF THE INVENTION
The present invention relates to synthetic peptides and method to use these synthetic peptides in an improved immunoassay for antibodies to HTLV-II.
10
2. DESCRIPTION OF THE PRIOR ART
Human T-Cell Lymphotropic Viruses (HTLV) types I and II are closely related human retroviruses. HTLV-I is associated with adult T-Cell Leukemia,
15 while HTLV-II although not associated with a specific disease, is found in many intravenous drug users. R. Lai et al., Serologic Discrimination of Human T Cell Lymphotropic Virus Infection by Using a Synthetic Peptide - Based Enzyme Immunoassay. J. of
20 Inf. Dis. 163:41-46 (January, 1991). Generally, serological assays cannot reliably distinguish between HTLV-I and HTLV-II infections. To serologically distinguish between these two viruses Lai et al., have disclosed synthetic peptides
25 corresponding with unique regions of the envelope glycoprotein (gp46) of human T-Cell lymphotropic viruses. In the Lai et al. study two synthetic HTLV-I sequence derived peptides, Env-1 (amino acids 191-215) and Env-5 (amino acids 242-257) , reacted
30 with 92% and 100% of serum specimens from HTLV-I infected person; although a small percentage (8.6%) of serum specimens from persons infected with HTLV- II cross-reacted with Env-1, none of these specimens reacted with Env-5. Peptide Env-2 encoded by the envelope region of HTLV-II (amino acids 187-210) reacted with serum specimens from both HTLV-I (94%) - and HTLV-II (74%) - infected patients, whereas as Env-6, another HTLV-II peptide (amino acids 238-254) reacted with less than 6% of the specimens. Based on this work Lai et al. , concluded that the Env-5 peptide represents an immunodominant domain of HTLV-
I that is recognized by serum antibodies from all HTLV-I infected persons. Thus, an assay using the
Lai et al. Env-5 peptide may allow for a categorical distinction between the closely related HTLV-I and
II infections. In the Lai et al. paper the peptides " were coated onto polyvinyl plates to perform the serological assessment of antibodies to HTLV-I or II. The HTLV-II peptide (Env-2) was attached to a microparticle by the present inventors. This solid phase, however, resulted in a serological assay for HTLV--II with low sensitivity. As such, a need exists to devise a peptide that could be used with microparticles to obtain a high sensitivity serological assay for HTLV-II. In the context of blood banking a serological test for HTLV-II would be useful.
SUMMARY OF THE INVENTION
The present invention relates to certain peptides corresponding to a portion of the glyco- protein gp-46 encoded by HTLV-II env gene, having the basic sequence disclosed by Lai et al. The improvement discovered by the inventors involves adding three amino acids homologous to HTLV-I prior to amino acid 187 of the Lai et al., HTLV-II peptide. Serine was also added at amino acid 183 of HTLV-II i The amino acid residue numbering is from the amino terminus of each protein. Additionally, certain amino acids may be added to the modified peptide to facilitate coupling to a solid phase. Surprisingly, this peptide modified to increase sensitivity to HTLV-I resulted in a highly sensitive solid phase assay for HTLV-II.
In particular, this invention relates to an antigen peptide of the formula: (Sequence Id. No. 1) . In addition tyrosine, cysteine or lysine may be added at either the N or C terminal end of the peptide. These modified peptides have the amino acid sequences shown in Sequence Id. Nos. 2-7. - These peptides (Sequence Id. Nos. 1-7) can be adsorbed or attached to a solid phase for use in an assay for the detection of HTLV-II specific antibodies. The method involves contacting the sample with the peptide under conditions such that an im unological complex will form between the peptide and antibodies to HTLV-II present in the sample, if such antibodies are present in the sample, and measuring the formation, if any of the immunological complex to determine the presence of antibodies to HTLV-II in the sample. This method is described in Example 3.
DETAILED DESCRIPTION OF THE INVENTION Renu Lai et al. have published the following amino acid sequences for part of the envelope gene for the HTLV-I and HTLV-II respectively, Sequence Id. No. 8 (corresponding to amino acid 191 to 214 of the natural peptide) ; and Sequence Id. No. 9 (corresponding to amino acid 187 to 210 of the natural peptide) . The amino acid residue numbering is from the amino terminus of each protein. Renu Lai et al. claimed that these sequences were important in distinguishing infection and immune response to HTLV-I and HTLV-II.
In making the synthetic peptides (Sequence Id. Nos. 1-7) of this invention the inventors combined the sequence published by Lai et al. for HTLV-II (Sequence Id. No. 8) , with a portion of a sequence for HTLV-I: Sequence Id. No. 10 (numbered from amino acid 187 to 214) published by Seiki et al. , Human Adult T-Cell Leukemia Virus: Complete Nucleotide Sequence of the Provirus Genome Integrated in Leukemia, Cell DNA,- Proc. Nat'l Acad. Sci. (USA) 80, 3618-3622 (June 1983) . Sequence Id. No. 10 was used to construct the sequence shown in Sequence Id. No. l. In particular one can see homology between amino acids 2-4 of Sequence Id. No. iθ and amino acids 2-4 Sequence Id. No. 1. The incorporation of a peptide sequence corresponding to HTLV-I (env) in an assay for anti-HTLV-I would be expected to broaden the antigenic spectrum to detect both HTLV-I and II.
Thus the amino acids at the N-terminus of the Lai et al. HTLV-II peptide was extended to include a short sequence of amino acids common with the amino acid sequence of the HTLV-I peptide. Additionally, amino acid Serine was added to the Lai et al. peptide.
This was thought to help discriminating HTLV-I from HTLV-II samples. Finally, lysine was added to the N-terminus of the peptide to facilitate coupling or adsorption to a solid phase such as a microparticle. Tyrosine (Y) or cysteine (C) may also be added instead of lysine (K) at either N or C terminal end of the peptide. Surprisingly, however, this peptide modified to increase sensitivity to HTLV-I resulted in a highly sensitive solid phase assay for HTLV-II.
The new peptides shown by Sequence Id. Nos. 1-7 can be coupled or adsorbed to a solid phase such as a microparticle. It is understood that the microparticle may be magnetic. This immunoreactant can react with antibodies to HTLV-II in a blood sample. The extent of the reaction between the synthetic antigen and the antibody in solution can be detected with a marked antibody that immunologically reacts with human HTLV-II. In the context of this invention the term marked means either directly or indirectly. To be indirectly marked a substrate for the bound enzyme is added.
Peptides were synthesized in the amide form on a Milligen-Biosearch 9600 model peptide synthesizer using fluorenyl ethoxy carbonyl (FMOC) amino protection scheme and 1-3 diisopropyl carbodiimide coupling chemistry. The amide form of the sequence was adopted because it could be expected to more closely mimic the biologically active analogue than the free acid form. Activated amino acids were coupled to a 2,4,- dimethoxy benzhydrylamine resin. Peptide synthesis was monitored by ninhydrin analysis for all amino acids except proline for which an Isatin test was performed. The synthesized peptide was cleaved from the resin by Reagent R, which comprises trifluoroacetic acid, thioanisole, ethanedithiol and anisol in a volumetric ratio of 90:5:3:2.
"5 Peptides cleaved from resins were purified by high performance liquid chromatography (HPLC) , and characterized"by Porton PI 20 90 E Integrated Micro Sequencing system to confirm the correct sequence. Purity was ascertained by HPLC on a reverse phase 0 column using a linear gradient (A) 0.1 trifluoroacetic acid in H20 (B)0.1% trifluoroacetic acid in CH3CN) of 5% to 60% (B) in 45 minutes. Absorbance was followed at 230 nm.
5 'Example 1
Peptides (Sequence Id. No. 2) were passively coated onto paramagnetic microparticles according to the following procedure: 1 ml of 2.5% of weight/volume approx. 5 μ paramagnetic particles 0 consisted of a polystyrene surface were separated on a magnetic separator in a 5 ml size disposable sterile cryogenic vial (corning, cat # 25708) . The supernatant was removed and the particles resuspended with 1 ml of 70% ethanol for 10 minutes. 5 The particles were then separated as before and supernatant was removed. The particles were resuspended in 1 ml of 50 mM carbonate buffer, pH 8.3. The particles were separated as before and supernatant was removed. Further, washing procedure 0 with carbonate buffer was repeated twice as before and supernatant removed. To the slurry of particles was added 100 μl of peptide solution (1 mg/ml in 50 mM carbonate buffer, pH 8.3) and 900 μl of 50 mM carbonate buffer. The particles were resuspended and then tumbled for approximately 5 hours, at room temperature.
The passively adsorbed peptide particles were then separated on a magnetic separator, supernatant removed and particles resuspended in isotonic buffered saline with 0.05% Tween 20 detergent. The particles were further separated and resuspended three times in isotonic buffered saline. The coated particles are then resuspended in isotonic buffered saline at final particle concentration of 0.25% weight to volume.
Example 2
Peptides (Sequence Id. No. 2) were covalently coupled to carboxyl functionalized paramagnetic microparticles according to the following procedure: 1 ml of 2.5% weight/volume approx. 5 μm paramagnetic particles were separated on a magnetic separator in a 5 ml size disposable sterile cryogenic vial (corning, cat #25708) . The supernatant was removed and the particles were resuspended with 1 ml of 70% ethanol for 10 minutes. The particles were then separated as before and supernatant was removed. The particles were resuspended in 1 ml of 50 mM carbonate buffer, pH 8.3. The particles were separated as before and supernatant was removed.
Further, washing procedure with carbonate buffer was repeated twice as before and supernatant removed. To the slurry of particles was added 5 mg of 1- Ethyl-3- (3-Dimethylaminopropyl) carbodiimide hydrochloride and 1 ml of carbonate buffer. The particles were mixed thoroughly and then tumbled for 40 minutes. The activated particles then separated on a magnetic separator Supernatant was removed and the particles were resuspended in 1 ml of peptide solution (0.1% mg/ml in carbonate buffer, pH 8.3). The particles were mixed thoroughly and then added 4 mg of sulfo-N-hydroxy succini ide. Again, the particles were mixed thoroughly and then tumbled for approximately 5 hours.
The covalently coupled peptide particles were then separated on a magnetic separator. Supernatant was removed and the particles were resuspended in isotonic buffered saline with 0.05% Tween 20 detergent. The particles were further separated and resuspended three times in isotonic buffered saline. The coated particles were then suspended in isotonic buffered saline at final concentration of 0.25% weight to volume.
Example 3 A paramagnetic particle assay using particles coated with peptide as shown in Examples 1-2 was performed as follows: Human serum or plasma was diluted 1:100 in well buffer (20% neonate calf serum, 1.06 M sodium chloride 0.015 M Tris-HCL, pH 7.4, 0.018 M Phosphate buffer, pH 7.4 + 0.1, 0.09% sodium azide, and 0.45% NP-40 ). 50 ul of the diluted samples were added to each well of a Pandex black microtiter plate. Samples were tested in replicates of at least 2. Paramagnetic particles, coated with peptides as described in example 1 or 2, were added to each well (20 μl) . The plate was then placed at 42° C for 30 minutes.
Upon completion of the incubation, the particles in the wells were washed with 100 μl phosphate buffered saline and Tween-20 (2.06 g sodium phosphate dibasic, 0.318 g sodium phosphate monobasic, 0.5 ml Tween-20, 8.76 g sodium chloride, and l.Og sodium azide per liter; pH 7.4). During the wash steps, the paramagnetic particles were held in the microtiter plate well via a magnetic field applied to the bottom of the plate. Particles were washed in this manner five times.
Particles in each well were resuspended in 30 μl of particle resuspension buffer (4.346 g sodium phosphate dibasic, 0.524 g sodium phosphate monobasic, 8.76 g sodium chloride, and 1 g sodium azide per liter; pH 7.4). 20 μl of goat anti-human IgG (H + L) conjugate with β-Galactosidase
(conjugate) and diluted 1:2000 in conjugate dilution buffer (0.1 M Tris-HCL pH 7.5, 0.5 M sodium chloride, 5% glycerol, 5.25 mM magnesium chloride, 0.1% sodium azide and 20% neonate calf sera, pH 7.5 + .3) was then added to the wells. After incubation with conjugate for 15 minutes at 42° C the particles in the wells were washed five times with phosphate buffered saline and Tween-20 as described above to remove essentially all of the unbound conjugate. The Tween-20 in the wash solution enhanced the ' washing process and removed nonspecifically bound conjugate.
Finally the sixth wash with substrate solution followed by addition of 50 μl of a substrate solution of 4-methyl-umbelliferyl-β-D galactoside (MUG) was added to each well (0.178 MUG, 3.58 g tricine, 5.1 ml dimethyl sulfoxide, 30 ml methyl alcohol. 0.20 g sodium azide, 0.5 ml Tween-20, per liter, pH 8.5). The presence of β-galactosidase (i.e. : conjugate) in the wells triggered the cleavage of MUG to generate a fluorescent coumarin product. This reagent and conjugate were used as a sensitive detection system. Fluorescence (excitation wavelength 400 nm/emmision wavelength 450 nm) was measured at two timed intervals (i.e. 2 and 14 minutes) post MUG addition. The difference between the two values was a kinetic measurement of fluorescent product generation and is a direct measurement of conjugate and human IgG/IgM bound to the particles. Fluorescent values were converted to nM coumarin values using various concentrations of coumarin itself and its resultant fluorescence to establish a standard curve.
TABLE 1
PEPTIDES PASSIVELY ADSORBED ON PARTICLES:
Particles at 0.02% in a suspension buffer; Goat anti Human IgG (H+L) β-Galactosidase labeled conjugate at 1:2000 dilution. An assay value of one hundred was set as the assay cutoff, and values less then one hundred were thus considered negative in this evalution.
TABLE 2
PEPTIDES COVALENTLY COUPLED PARTICLES:
Particles at 0.02% in a suspension buffer; Goat anti Human IgG (H+L) β-Galactosidase labeled conjugate at 1:2000 dilution. An assay value of one hundred was set as the assay cutoff, and values less than one hundred were thus considered negative in this evalution.
These examples show that synthetic peptide of Sequence Id. No. 2 attached or associated with a solid phase, such as a microparticle, results in a more sensitive assay for HTLV-II than the HTLV-II peptide reported by Lai et al.
Although the invention has been described primarily in connection with special and preferred embodiments, it will be understood that it is capable of modification without departing from the scope of the invention. The following claims are intended to cover all variations, uses, or adaptations of the invention, following, in general, the principles thereof and including such departures from the present disclosure as come within known or customary practice in the field to which the invention pertains, or as are obvious to persons skilled in the field.
SEQUENCE LISTING (1) GENERAL INFORMATION:
(i) APPLICANT: Shah, Dinesh O. Nath, Nrapendra (ii) TITLE OF INVENTION: Synthetic Peptides Corresponding to a Portion of HTLV-II Virus and Method To Use the Same in an Improved Immunoassay (iii) NUMBER OF SEQUENCES: 10 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Baxter Diagnostics Inc.
(B) STREET: One Baxter Parkway, DF2-2E
(C) CITY: Deerfield
(D) STATE: Illinois (E) COUNTRY: USA
(F) ZIP: 60015 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentln Release #1.0, Version #1.25
(Vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: US (B) FILING DATE:
(C) CLASSIFICATION: (viii) ATTORNE /AGENT INFORMATION:
(A) NAME: Barta, Kent
(B) REGISTRATION NUMBER: 29,042 (C) REFERENCE/DOCKET NUMBER: PA-4196
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 708/948-3308
(B) TELEFAX: 708/948-2642 (2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids
(B) TYPE: amino acid (C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: Ser Pro Pro Leu Val His Asp Ser Asp Leu Glu His Val 1 5 10
Leu Thr Pro Ser Thr Ser Trp Thr Thr Lys lie Leu Lys
15 20 25
Phe He 28 (2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Lys Ser Pro Pro Leu Val His Asp Ser Asp Leu Glu His 1 5 10 Val Leu Thr Pro Ser Thr Ser Trp Thr Thr Lys He Leu 15 20 25
Lys Phe He 29 (2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids
(B) TYPE: amino acid (C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide
(Xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Ser Pro Pro Leu Val His Asp Ser Asp Leu Glu His Val 1 5 10
Leu Thr Pro Ser Thr Ser Trp Thr Thr Lys He Leu Lys
15 20 25
Phe He Lys 29
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids
(B) TYPE: amino acid (C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown (ii) MOLECULE .TYPE: peptide ( i) SEQUENCE DESCRIPTION: SEQ ID NO:4: Tyr Ser Pro Pro Leu Val His Asp Ser Asp Leu Glu His 1 5 10
Val Leu Thr Pro Ser Thr Ser Trp Thr Thr Lys He Leu
15 20 25
Lys Phe He 29 (2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide ( i) SEQUENCE DESCRIPTION: SEQ ID NO:5: Ser Pro Pro Leu Val His Asp Ser Asp Leu Glu His Val 1 5 10
Leu Thr Pro Ser Thr Ser Trp Thr Thr Lys He Leu Lys
15 20 25
Phe He Tyr 29
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids
(B) TYPE: amino acid (C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Cys Ser Pro Pro Leu Val His Asp Ser Asp Leu Glu His 1 5 10
Val Leu Thr Pro Ser Thr Ser Trp Thr Thr Lys He Leu
15 20 25
Lys Phe lie 29 (2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Ser Pro Pro Leu Val His Asp Ser Asp Leu Glu His Val 1 5 10 Leu Thr Pro Ser Thr Ser Trp Thr Thr Lys He Leu Lys 15 20 25
Phe He Cys 29 (2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids
(B) TYPE: amino acid (C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Leu Pro His Ser Asn Leu Asp His He Leu Glu Pro Ser 1 5 10
He Pro Trp Lys Ser Lys Leu Leu Thr Leu Val
20 (2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS: ' (A) LENGTH: 24 amino"acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown
(D) TOPOLOGY: unknown (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
Val His Asp Ser Asp Leu Glu His Val Leu Thr Pro Ser 1 5 10
Thr Ser Trp Thr Thr Lys He Leu Lys Phe He 15 20 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown
(ii) MOLECULE TYPE: peptide
( i) SEQUENCE DESCRIPTION: SEQ ID NO:10: Ala Pro Pro Leu Leu Pro His Ser Asn Leu Asp His He
1 5 10
Leu Glu Pro Ser He Pro Trp Lys Ser Lys Leu Leu Thr
15 20 25
Leu Val
28

Claims (8)

WE CLAIM:
1. A serological method for detection of antibodies to HTLV-II in a blood sample comprising: a) covalently attaching a synthetic peptide selected from the group consisting of amino acids shown in Sequnce Id. Nos. 1, 2, 3, 4, 5, 6, and 7, to a solid phase; b) combining said solid phase with a blood sample; c) detecting antibodies to HTLV-II bound to said solid phase.
2. The method of Claim 1 wherein said solid phase ,is a microparticle.
3. A serological method for detection of antibodies to HTLV-II in a blood sample comprising: a) adsorbing a synthetic peptide selected from the group consisting of amino acids shown in Sequence Id. Nos. 1, 2, 3, 4, 5, 6, and 7 to a solid phase; b) combining said solid phase with a blood sample; c) detecting antibodies to HTLV-II bound to said solid phase.
4. The method of Claim 3 wherein said solid phase is a microparticle.
5. A synthetic peptide consisting of the amino acids shown in Sequence Id. No. 1.
6. An immunological reagent comprising a synthetic peptide compound capable of binding to antibodies to HTLV-II coupled or adsorbed to a solid phase said peptide selected from the group of peptides represented by the following N-terminal to C- terminal amino acid sequences coupled or adsorbed to a solid phase said:
7. The method of Claim 8 wherein said solid phase is a microparticle.
8. A diagnostic test kit for the detection of HTLV- II specific antibodies comprising: a) microparticles coated with synthetic peptides selected from the group consisting of amino acids shown in Sequence Id. Nos. l, 2, 3, 4, 5, 6, and 7; b) a vial of marked antibody that immunologically reacts with human HTLV-II antibody; c) a positive control; d) a negative control; and e) microtiter plates.
AU31425/93A 1991-11-25 1992-11-20 Immunoassay using synthetic HTLV-11 peptides Ceased AU660752B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79755791A 1991-11-25 1991-11-25
PCT/US1992/009973 WO1993011431A1 (en) 1991-11-25 1992-11-20 Immunoassay using synthetic htlv-ii peptides
US797557 2001-04-23

Publications (2)

Publication Number Publication Date
AU3142593A true AU3142593A (en) 1993-06-28
AU660752B2 AU660752B2 (en) 1995-07-06

Family

ID=25171175

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31425/93A Ceased AU660752B2 (en) 1991-11-25 1992-11-20 Immunoassay using synthetic HTLV-11 peptides

Country Status (5)

Country Link
EP (1) EP0573630A4 (en)
JP (1) JPH06506479A (en)
AU (1) AU660752B2 (en)
CA (1) CA2100883A1 (en)
WO (1) WO1993011431A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2159291T3 (en) * 1992-02-24 2001-10-01 Genelabs Tech Inc METHOD AND ANALYSIS OF HTLV-I / HTLV-II.
US7166439B2 (en) * 2002-03-01 2007-01-23 Gmp Endotherapeutics, Inc. Assay for anti-INGAP antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070246A (en) * 1976-04-09 1978-01-24 Abbott Laboratories Reactive matrices
US4070247A (en) * 1977-03-30 1978-01-24 Indiana University Foundation Diagnostic media
US5039604A (en) * 1987-08-21 1991-08-13 Cellular Products, Inc. Test device and method of preparing same, assay kit and method for the simultaneous detection of two HTLV or HIV antibodies
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
SE8900721D0 (en) * 1989-03-02 1989-03-02 Blomberg Jonas METHODS FOR DETECTION OF ANTIBODIES TO
FI910245L (en) * 1990-01-24 1991-07-25 United Biomedical Inc SYNTHETICS PEPTIDKOMPOSITIONER MED IMMUNOREACTIVITET MOT HTLV-ANTIKROPPAR.
NZ238855A (en) * 1990-07-18 1994-03-25 Iaf Biochem Int Peptides, mixtures thereof and compositions useful for detecting htlv-i and htlv-ii infections

Also Published As

Publication number Publication date
AU660752B2 (en) 1995-07-06
CA2100883A1 (en) 1993-05-26
EP0573630A4 (en) 1995-07-12
JPH06506479A (en) 1994-07-21
EP0573630A1 (en) 1993-12-15
WO1993011431A1 (en) 1993-06-10

Similar Documents

Publication Publication Date Title
EP0199438B1 (en) Htlv iii polypeptides
US20020042045A1 (en) METHODS FOR THE DETECTION OF HTLV-II ANTIBODIES EMPLOYIING NOVEL HTLV-II nra ENVELOPE PEPTIDES
WO1995001457A9 (en) Htlv-iinra compositions and assays for detecting htlv infection
JP2994031B2 (en) Method for determining the presence or amount of HIV-1 or HIV-2 antibody, immunospecific reagent, synthetic peptide, diagnostic kit, method for preparing HIV-1 or HIV-2 antibody, immunogen and antibody
JPH0751598B2 (en) Synthetic peptide antigen for detecting HTLV-1 infection
US5260189A (en) Synthetic HIV-like peptides their compositions and uses
WO1992022571A1 (en) Immunoassay for non-a non-b hepatitis
SE467542B (en) SYNTHETIC PEPTIDE ANTIGENS, IMMUNIZING COMPOSITION AND IMMUNAL ANALYSIS FOR HTLV-1 ANTIBODIES
AU660752B2 (en) Immunoassay using synthetic HTLV-11 peptides
US5283320A (en) Peptides for HTLV-2 infection diagnosis of, therapy for, vaccination against, for distinguishing between HTLV-1 and HTLV-2 infections and antibodies derived therefrom
AU657590B2 (en) Synthetic peptides corresponding to portions of HIV-2 virus and methods of using in an improved assay
EP0532746B1 (en) Assay for non-a non-b hepatitis
JP2002511853A (en) HIV antibody detection method and antigen used therefor
JP2002501930A (en) Peptide structures and their use in the diagnosis of herpes simplex virus type 2
CA2004287A1 (en) Peptides
DE DK et al. HCV MOSAIK ANTIGEN ZUSAMMENSETZUNG COMPOSITION D’ANTIGENE MOSAIQUE DU VIRUS DE L’HEPATITE C (VHC)
JP2007224043A (en) Peptide structures and their use in the diagnosis of herpes simplex virus type 2